Advertisement

Role of tirofiban in the medical treatment of the intermediate-risk patient with an acute coronary syndrome cannot be denied

      The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) trial compared tirofiban with heparin in the treatment of 3,232 patients. The admission criteria were chest pain within the preceding 24 hours and either electrocardiographic changes (ST depression in 32%), transient (<20 minutes) ST elevation or T-wave inversion (in 75%), elevated cardiac enzymes, or a history of coronary artery disease.

      [No authors listed]. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498–1505.

      The drugs were infused in a double-blind manner for a total of 48 hours. In addition, patients received aspirin therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. [No authors listed]. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498–1505.

        • Robertson G.C.
        Management of intermediate coronary syndrome.
        Am J Cardiol. 2000; 85: 21B-26B
      2. [No authors listed]. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;38:1488–1497.